Drug discovery and development is costly and time consuming, with high drug failure rates early in the development process. Cardiac safety, toxicity and efficacy testing, usually performed using animal models or primary human cells, are one of the main reasons for high drug attrition rates.
Human iPSC-based cell models promise to bridge the gap between high-content screening and clinical studies. However, a suitable technology is required to acquire high quality data at high throughput.
The FLEXcyte technology greatly enhances the evaluation of drug candidates in cardiac safety, toxicity and efficacy testing, as well as basic research. It was validated with a broad range of commercially available human iPSC-derived cardiomyocytes, deliberately chosen as the most predictive and relevant cellular model available.
Standard cultivation methods are still based on stiff glas or plastic surfaces. Both is far from the physiological environment cells would experience naturally. The FLEXcyte plates produced by innoVitro simulate the mechanical conditions of real biological tissue. As a result the development of a mature phenotype of the cultured cells is achieved. At the same time, the plates are as easily handled as standard 96-well plates. In combination with the FLEXcyte 96 platform by Nanion Technologies it is even possible to measure the contractility of the cultured cells.
"We were very pleased with our choice to engage innoVitro’s contractility service. The studies using human iPSC-derived cardiomyocytes were tailored to our needs to provide results comparable to already existing (in house) data and the fast execution followed by a comprehensive study report completed the service perfectly."Nina Glaser,
Head of Early Safety Electrophysiology,
Merck Healthcare KGaA